Impact of Everolimus-Induced Pneumonitis on Metastatic Renal Cell Carcinoma
Everolimus-induced pneumonitis was associated with improved clinical outcomes in patients with metastatic renal cell carcinoma and possibly may be recognized in the future as an indicator of the drug’s efficacy, according to new research published by P. Penttilä, MD, of the Comprehensive Cancer Center, Helsinki University Hospital, Finland, and colleagues, in the European Journal of Cancer.
Since mammalian target of rapamycin inhibitors such as everolimus may induce pneumonitis in patients receiving the drug, the investigators sought to analyze the association of pneumonitis and clinical outcomes in two independent cohorts of patients with metastatic renal cell carcinoma. A total of 85 patients who received everolimus at Helsinki University Hospital made up cohort A, and 148 patients who received the drug at Aarhus University Hospital were included in cohort B.
In both cohorts, the incidence of pneumonitis was associated with longer overall and progression-free survival, as well as improved clinical benefit rates. Based on these results, the investigators concluded: “Everolimus-induced pneumonitis is associated with improved outcome in patients with metastatic renal cell carcinoma and may serve as a biomarker of everolimus efficacy.”